Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Increasingly Seems Focused On Combo Therapy In NASH

Executive Summary

At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.

Advertisement

Related Content

Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets
NASH News & Notes From The European Liver Meeting
Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen
NASH Pipeline: Racing To The Finish
Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Combination Strategies A Common Thread In NASH R&D
Gilead Faces Challenges In HCV, But Competitors Would Switch Places

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125061

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel